Can a Nasal Decongestant Test Predict Treatment Outcomes in Seasonal Allergic Rhinitis?
Information source: University of Chicago
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Seasonal Allergic Rhinitis
Intervention: mometasone furoate nasal spray (Drug); placebo (Drug)
Phase: N/A
Status: Completed
Sponsored by: University of Chicago Official(s) and/or principal investigator(s):
Robert M Naclerio, MD, Principal Investigator, Affiliation: University of Chicago
Summary
We hypothesize that those patients with purely seasonal allergic rhinitis will decongest
better than those subjects with another cause contributing to their symptoms. These latter
patients will not improve as well on an intranasal steroid as those who decongest well,
potentially explaining the 60% response rate in prior studies.
Clinical Details
Official title: Does the Response to a Nasal Decongestant Test Predict the Outcome to Treatment of Seasonal Allergic Rhinitis With Nasonex?
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)
Primary outcome: Global Assessment
Secondary outcome: Changes in RQLQ: OverallChanges in RQLQ: Activity Changes in RQLQ: Sleep Changes in RQLQ: Non-Nasal/Eye Changes in RQLQ: Practical Changes in RQLQ: Nasal Changes in RQLQ: Emotional Changes in RQLQ: Eye
Eligibility
Minimum age: 18 Years.
Maximum age: 60 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria
1. Males and females between 18 and 60 years of age.
2. History of grass and/or ragweed allergic rhinitis.
3. Positive skin or RAST test to grass, trees and/or ragweed antigen.
4. Symptomatic at time of entry into study.
Exclusion Criteria
1. Women of childbearing potential not using the contraception method(s) (Birth control
pills, depo Provera, double barrier) as well as women who are pregnant or
breastfeeding.
2. Patients with severe medical condition(s) that in the view of the investigator
prohibits participation in the study (heart, lung, kidney, neurological, oncologic or
liver disease).
3. Use of any other investigational agent in the last 30 days.
4. Absence of nasal symptoms.
5. Smoking.
6. URI at the time of screening.
Locations and Contacts
University of Chicago, Chicago, Illinois 60637, United States
Additional Information
Starting date: April 2008
Last updated: January 21, 2014
|
